ProSci Incorporated

Founded in 1998 to support HIV vaccine research, ProSci has utilized its infectious disease expertise to develop exceptional, high-quality antibodies, recombinant proteins, and other reagents for a vast number of research areas. As one of the first companies to market COVID-19 products, ProSci holds a broad catalog of SARS-CoV-2 reagents and is continuously expanding our portfolio. ProSci also specializes in custom monoclonal, polyclonal, and single domain antibody development. Using several techniques including hybridoma technology, plasma cell cloning, and phage display, we can create antibodies that target the most difficult antigens that you can find. Call us for a free consultation to develop the perfect antibody for you.